About
Bernard Peperstraete, MD, is CEO and President of Acuamark Diagnostics, Inc. Acuamark Diagnostics was spun out of the Barany Labs at Weill Cornell Medicine, and focuses on developing a highly accurate, convenient and scalable test for early detection of cancer out of blood. Relative to other approaches in development for early cancer detection (traditional qPCR and NGS), AcuamarkDx proposes a differentiated solution. Acuamark Diagnostics' scientific and academic team is credited with inventing groundbreaking assays such as the ligase chain reaction (LCR), the ligase detection reaction (LDR), the universal array and qPCR (TaqMan). Prior to Acuamark Diagnostics, Bernard served as Acting President and CEO of ACT Biotech, a cancer pharmaceutical company, which was acquired by Eddingpharm. Earlier, Bernard was involved in healthcare venture capital for nearly a decade, most recently as a Partner at NGN Capital. As an investor, Bernard served on the boards of Potentia Pharma (now Apellis P
Position in the VCSift Database
- • 287 investors hold the President & CEO role in VCSift. Bernard Peperstraete is one of them.
- • 10,621 investors are based in New York, New York, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- New York, US
Contact Information
Find more investors like Bernard
Search Investors